Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg significantly reduces major adverse cardiovascular events (MACE), heart failure composite endpoints, cardiovascular death, and all-cause death in patients with atherosclerotic cardiovascular disease and obesity, regardless of whether they have heart failure with preserved or reduced ejection fraction.
If you have heart disease and are overweight or obese, especially if you have heart failure, asking your doctor about once-weekly semaglutide (2.4 mg) could significantly lower your risk of heart attacks, strokes, heart failure hospitalizations, and death. This benefit applies whether your heart pumps strongly or weakly, and it is safe to use alongside your current heart failure medications.
Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60–0·87 for MACE; 0·79, 0·64–0·98 for the heart failure composite endpoint; 0·76, 0·59–0·97 for cardiovascular death; and 0·81, 0·66–1·00 for all-cause death; all pinteraction>0·19).
Why this rating
Based on a large, randomized, double-blind, multicentre, placebo-controlled phase 3 trial (SELECT) with 17,604 patients.
Source
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
John Deanfield et al. · The Lancet · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →